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Abstract
Background: With an increasing number of imaging studies being done nowadays, the number of incidentally
discovered thyroid nodules is expected to rise. Although many of these nodules are small and benign in nature,
some do grow and may cause pressure and/or thyrotoxic symptoms. Surgical resection has traditionally been
recommended for symptomatic nodules but is associated with risk of hypothyroidism, bleeding, infection, and
nerve damage. High intensity focused ultrasound (HIFU) is one of the non-surgical thermal ablation techniques that
may serve as an alternative in the treatment of benign thyroid nodules. The present review is to systematically
evaluate the efficacy and safety of HIFU ablation.
Methods: We comprehensively searched all studies that evaluated the use of HIFU ablation as a treatment of
benign thyroid nodules from Medline (PubMed) and Cochrane Library electronic databases using specific keywords.
All titles identified by the search strategy were independently screened by two authors. Case reports, animal
studies, editorials, expert opinions, reviews without original data and studies on pediatric population were excluded.
Multiple reports of the same dataset were assessed and the most representative and updated report of a study was
included.
Results: Five original studies were found. All treated thyroid nodules were confirmed to be benign cytologically
and either appeared solid or predominantly (>70%) solid on ultrasonography. Only one type of commercially
available US-guided device with an extracorporeal probe (3 MHz) was used in all the reported treatments. No major
complications including recurrent laryngeal nerve injury, skin burn or haematoma were reported in all of the
studies. The overall nodule volume reduction after single session of HIFU ablation ranged between 45 and 68%,
depending on nodule size and length of follow-up.
Conclusions: Despite the few number of studies, our review appeared to suggest that HIFU is a safe and
efficacious method of treating symptomatic benign thyroid nodules. However, larger-scale, prospective trials with
longer follow-up period are indeed required to confirm this. In terms of the ablation itself, relative to other ablation
techniques, there are still much room for improvements in shortening treatment duration and expanding the range
of treatable nodules.
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Background
Thyroid nodules are common and can be discovered on
clinical palpation in 5% of normal individuals and in
60% by high-resolution ultrasonography (US) [1, 2].
However, most of these nodules are small and often dis-
covered incidentally while patients undergo imaging for
conditions unrelated to the thyroid gland [1, 2]. Fine
needle aspiration cytology (FNAC) could often confirm
that the majority (>95%) of these nodules are benign [1]
and given that most do not cause symptoms, no treat-
ment would be needed except for a repeat US assess-
ment a few years later [1–5]. Nevertheless, there is a
potential for a select group of nodules to grow over time
and cause local pressure symptoms like neck pain, occa-
sional choking, dyspnea and dysphagia or hyperthyroid-
ism. A recent multi-center, observational study has
reported that up to 15% of benign nodules grow con-
tinuously in an accelerated matter while the rest remains
relatively static in size [3]. From a clinical point of view,
perhaps, an early identification and intervention of these
growing nodules (irrespective of their symptoms) would
benefit patients in the long term.
However, the choice of early intervention available has
been limited. Surgical resection has traditionally been
the recommended treatment for symptomatic or grow-
ing benign thyroid nodules. The revised American Thy-
roid Association (ATA) recommended that surgical
resection (in the form of a hemithyroidectomy or a total
thyroidectomy) be considered when a benign solid or
predominantly solid nodule is either large-in-size (>4 cm
in diameter) or is causing compressive local symptoms
or clinical concern [3]. However, surgery is associated
with risk of hypothyroidism, bleeding, infection, voice
hoarseness from recurrent laryngeal nerve injury
which may or may not be permanent [1, 6]. Moreover,
surgery requires a general anesthesia and may not be
feasible in some individuals because of underlying
medical morbidities [1–6].
As a result, less-invasive, non-surgical techniques have
to be developed [7]. This has led to the introduction of
non-surgical, minimally invasive techniques like percu-
taneous ethanol injection (PEIT) [7, 8] and image-guided
thermal ablation techniques like laser ablation therapy
(LAT) and radiofrequency ablation (RFA) [9–11]. PEIT is
effective in thyroid cysts and is recommended for recur-
rent, benign thyroid cysts [7, 8] but for solid or
predominantly-solid nodules, thermal ablation techniques
like LAT and RFA are generally more effective [9–11].
Studies have found these techniques could not only result
in >50% nodule size reduction but also relieve pressure
symptoms in many patients [9–11].
High intensity focused ultrasound (HIFU) is one of
these emerging thermal ablation techniques but has
been less well described in the literature. Its major
advantage over other thermal techniques is that it could
induce a focused thermal tissue destruction of up to 85 °C
without needing needle puncture and skin penetration
[12]. This technique has been successfully applied to a
wide variety of benign and malignant tumors in the pan-
creas, prostate, bone, liver and breast [13]. However, the
clinical application of HIFU for benign thyroid nodules
has been somewhat limited [7].
Pre-clinical studies on HIFU
To date, two animal studies have looked at the feasibility
of using this technology to induce a well-defined lesion
in a thyroid lobe, while leaving surrounding tissues un-
ablated [12, 14]. The authors initially used a device that
was intended for HIFU prostate treatment. In their first
study, 13 thyroid lobes (mean volume, 3.4 cm3) from
eight ewes were subjected in vivo to the HIFU beam.
The thyroid lobes of the ewe that were excised 13 days
after HIFU treatment. On microscopy, the ablated area
exhibited a well-defined central necrotic area with loss
of tissue architecture and colonization of the central
area with polymorphonuclear leukocytes [12]. Based on
these findings, the authors concluded that HIFU was an
effective energy source for thyroid ablation [12, 14].
Clinical application
The first-ever clinical study was a single center, open-
label trial conducted from 2003 to 2006 by the same
French group that carried out the two animal studies
[15]. Together, 25 patients were treated with an US-
guided HIFU device two weeks before their scheduled
thyroidectomy for a benign multinodular goiter. The
device used was a computer-driven system composed of
an electronics cabinet, an extracorporeal probe (3 MHz
frequency) mounted on a gantry and moved by stepper
motors, a cooling unit, and an ultrasound-imaging
scanner (7.5 MHz 128 element imaging linear array).
The amount of depth-independent pulse acoustic energy
received by each nodule ranged from 35 to 94 joules.
Thyroid US and thyroid function were evaluated before
and after treatment. Three (12.0%) patients discontinued
the HIFU treatment due to intolerable pain. Among the
remaining 22 patients, 16 (72.7%) had significant echo-
genic changes on US following the treatment. Macro-
scopic and histological examinations showed that all
treated lesions were confined to the targeted area with-
out affecting neighboring structures. At pathological
analysis, the extent of nodule destruction ranged from 2
to 80%. In the last three patients ablated at the highest
energy level, significant US changes and complete
coagulative necrosis were observed in 80, 78, and 58%
within the targeted area, respectively. There were no
major complications of ablation ablated at the highest
energy level [15]. However, despite the success of the
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first human study, the general adoption of this technique
in routine clinical practice has been slow. To date, few
clinical studies have evaluated the efficacy of HIFU treat-
ment for benign thyroid nodules. In the United States,
the use of US-guided HIFU device has been under re-
view by the Federal and Drug Association (FDA) as a
treatment option for benign thyroid nodules. Given the
scarcity of evidence, the present review aimed to com-
prehensively evaluate the efficacy and safety of HIFU
treatment of patients with benign thyroid nodule from
the current literature.
Methodology
To comprehensively review the current literature, we
electronically retrieved all studies that evaluated the use
of HIFU in the treatment of benign thyroid nodules
from Medline (PubMed) and Cochrane Library elec-
tronic databases. The search was carried out on 27th
October 2016. We used the following free text search
terms in “All fields”
#1: ‘high intensity focused ultrasound’
#2: ‘focused ultrasound’
#3: ‘thyroid nodule’
#4: ‘thyroid neoplasm’
#5: #1 OR #2 AND #3 or #4
There was no language restriction or methodological
filters. The bibliographies of eligible studies were
searched for other additional relevant references. All
titles identified by the search strategy were independ-
ently screened by two authors (ALW, BHL). Search re-
sults were compared, and disagreements were resolved
by consensus. Abstracts of potentially relevant titles
were then reviewed for eligibility and full-length articles
were selected for closer examination. Since there were
no randomized trials, any prospective or retrospective
study was included. However, case reports, animal studies,
editorials, expert opinions, reviews without original data
and studies on pediatric population were not included. In
case of multiple reports on the same dataset, only the
most representative and updated report was selected.
All data were extracted onto a standardized form. The
primary data extracted from each article included num-
ber of nodules ablated by HIFU, mean size (volume) of
ablated nodules, device used, amount of energy delivered
per treatment, treatment time, treatment-related compli-
cations and efficacy (or % of nodule shrinkage) at any
time points following treatment.
Outcomes measured
These included treatment efficacy (i.e. extent of nodule
shrinkage (%) within the first year from baseline as
determined by serial US assessments), changes in symp-
toms and incidence of treatment-related complications.
Results
Eleven articles were identified from our electronic search
and of these, 2 were review articles [7, 16], 1 was a case
report [17], 1 was an animal study [14] and 1 was an edi-
torial [18]. Therefore, 6 articles were deemed to be
original articles. Of these, 2 studies [19, 20] appeared to
share similar set of patient data and so the least inform-
ative article [20] was excluded. Therefore, in the end,
only 5 studies [15, 19, 21–24] were considered to con-
tain original data. No additional study was found from
our search of the bibliographies of the two review arti-
cles [7, 16]. In terms of country of origin, the first pub-
lished article came from France [15]. This was followed
by 3 studies from Germany [19, 21, 22], 1 study from
Bulgaria [23] and 1 from Hong Kong, China [24].
Case selection
Table 1 compares the inclusion and exclusion criteria of
the 5 studies [15, 19, 21–24]. All studies included cyto-
logically benign nodules that appeared solid or predom-
inantly (>70%) solid on US [15, 23, 24]. Thyroid nodules
were generally confirmed benign on at least one FNAC
or trucut biopsy [23, 24]. Nodules that were indetermin-
ate or suspicious of malignancy on FNAC were not
treated by HIFU ablation. Limited neck extension was
one of the most exclusions, because patients generally
had to extend their neck during treatment [15, 23,
24]. A majority of studies only selected nodules that
were causing pressure symptoms, cosmetic concern or
hyperthyroidism [19, 21, 24]. Interestingly, there was
no upper size limit imposed on the treated nodules.
However, 2 studies did set a lower size limit at > =
10 mm [23, 24].
Assessment of response
US and US Doppler were the two common treatment
assessment modalities. For US Doppler, nodules were clas-
sified into type 1 (no nodular flow), type 2 (minimal flow)
and 3 (significant blood flow) [19, 23]. One group also per-
formed 99mTc-pertechnetiate scintigraphy to measure the
change in 99mTC uptake before and after HIFU treatment
[19]. The authors showed that the median nodular 99mTc-
MIBI uptake was reduced by 35.5%, while the median up-
take reduction for 99mTc scintigraphy was 27% [19].
Among these 5 studies, only one study used visual
analogue scale was used to monitor the change in symp-
toms or cosmesis after treatment [24].
Technique and equipment
From the literature, it seems that only one US-guided
device for the treatment of thyroid nodules was
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available commercially [15, 19, 21–24]. This device
was known as EchoPulse®(Theraclion SA, Malakoff,
France). This particular device has 2 independent US
systems, one for real-time imaging guidance and the
other for HIFU energy delivery and treatment. Both
operates via the same probe by placing it over the
targeted treatment area. The US imaging system acts
as a guide for the treatment system and emitts fre-
quencies of 7.5–12 MHz (128 elements, linear array)
while the treatment system has a 60 mm dimeter
probe emitting 3 MHz pulses of up to 125 W of
maximum acoustic power. The imaging system is
placed in the midst of the probe such that the focal
point of the treatment system is always displaced in
the centre of the US image (Fig. 1). Hyperechoic
marks signifies the presence of micro-bubbles and im-
plies the treated area has reached a temperature
above 70–80 °C (Fig. 1).
Treatment safety and process
Given there is a number of vital heat-sensitive struc-
tures near the thyroid gland, physical limits have been
set on how close the treatment beam should be dur-
ing treatment. For example, the recommended safe
distance for the common carotid arteries from the
focus of the beam has been set at 0.2 cm, 0.3 cm for
the trachea, and 0.5 cm for the recurrent laryngeal
nerve. However, to date, none of these limits has
been correlated with any clinical data. The Echopulse
device is designed to automatically limit power on
these vital areas [15, 19, 21–24]. The treatment area
is planned manually into 10 to 20 sagittal and trans-
verse section plane. Once these areas have been de-
fined, the treatment area is further divided into voxels
of 0.2 cm in diameter and 0.9 cm in length. Each
voxel receives a HIFU pulse lasting over 4 to 8 s dur-
ation, raising the temperature between 60 and 80 °C,
Table 1 A literature summary of HIFU studies adapting different criteria
First author (year) Inclusion criteria Exclusion criteria
Esnault (2011) [15] - At least two thyroid nodules, with at least one for surgery
- Nodule targeted for HIFU located at least 3 mm from the
trachea, esophagus, recurrent nerve, carotid artery, skin
- Selected nodule for HIFU treatment was different from
the one indicated for surgery
- Suspicion of malignancy nodule, neck
irradiation, previous surgery, previous
radioactive iodine treatment
- Any cystic components ≥ 20% or any
large calcifications
- Patient unable to maintain a stable
position with hyperextended neck
Korkusuz (2014) [19] At least one benign thyroid nodule with associated
thyrotoxicosis, neck pain, throat hoarseness, swallowing
disorders, discomfort and/or cost concern.
- Malignant nodule
- Close to heat-sensitive structures like the
recurrent laryngeal nerve, trachea,
esophagus and carotid artery
Korkusuz (2015) [21] - Over 18 years old
- At least one benign thyroid nodule with associated issues
(neck pain, hoarseness, swallowing disorders, discomfort,
cosmetic concerns and/or thyrotoxicosis
- Refused surgery/RIT
- Malignant nodules
- Target nodules close to sensible structures
such as trachea, carotid arteries
- Patients who showed any contraindication
to HIFU (recurrent nerve anomalies, target
volumes not)
Korkusuz (2015) [22] - Patient with symptomatic nodule
- Cosmetic concerns
- Refused surgery or contraindicated
- Patients with asymptomatic nodules
- Nodule volume≥ 10 mL
- Histological evidence for malignancy
Kovatcheva (2015) [23] - Over 18 years old
- Presence of one or more thyroid nodules without signs
of malignancy
- A nodule measured on US ≥10 mm in three orthogonal
dimensions
- ≤30% of the targeted nodule is cystic
- HIFU accessibility of the targeted nodule
- Normal thyrotropin concentrations
- Absence of vocal cord immobility at laryngoscopy
- Head and/or neck disease which prevents
hyperextension of neck
- Past medical history of thyroid cancer or
other malignant tumors in the neck region
- History of neck irradiation
- Intra-nodular macro-calcifications which
precludes treatment with HIFU
- Nodules next to posterior margin of the
thyroid lobe with anteroposterior diameter
less than 15 mm
- Pregnancy/lactation
- Any contraindications related to intravenous
moderate sedation
Lang (2017) [24] - Benign cytology and low to very low suspicion
sonographic pattern
- Nodule believed to be causing pressure symptoms
- All 3 dimensions between 10 and 40 mm
- Nodule≥ 70% solidity
- Nodule within 5–30 mm from skin
- Normal thyroid function and calcitonin levels
- Age ≤ 18 years old
- Pregnant or lactating women
- Indeterminate or malignant nodules
- Intra-nodular macro-calcifications
- History of head and neck irradiation
- History of non-medullary thyroid carcinoma
- Pre-existing vocal cord palsy
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followed by a cooling period of 20 to 40 s, whilst the
probe is redirected to the adjacent voxel. Cooling is
provided by a cooling circulating liquid at 10 °C
within a plastic balloon positioned at the forefront of
the probe, preventing pre-focal tissue damage. During
treatment, patients’ vital signs are monitored.
Treatment efficacy
Table 2 shows a summary of the treatment results.
Esnault et al. conducted the first clinical series of 25 pa-
tients [15]. However, since these patients underwent thy-
roidectomy 2 weeks after ablation, the actual extent of
nodule shrinkage following HIFU could not be assessed.
The authors noted that on histology, nodule destruction
was observed in 22 of the 25 patients, with the
remaining 3 not assessed due to insufficient number of
HIFU shots received. There were no major complica-
tions except for skin blisters and pain only [15].
Korkusuz et al. conducted an open label study on 9
patients [19]. They used a similar US-guided HIFU de-
vice with a 3 MHz probe. The mean acoustic energy
used per pulse ranged from 87.6 to 192.8 joule per sec-
ond. Treatment efficacy was compared with the baseline
using US Doppler, 99mTc scintigraphy and 99mTc-MIBI
scintigraphy. The nodules’ volume and blood perfusion
were determined with the US Doppler. Median nodular
99mTc-MIBI uptake reduced by 35.5%, while the median
uptake reduction for 99mTc scintigraphy was 27%. Blood
perfusion was noted to decrease in 3 cases but their ex-
tent of nodule volume reduction was not documented.
At 3 months, the absolute nodule volume reduction
from baseline ranged from 0.4 to 4.7 ml and relative to
baseline, the % of volume reduction ranged from 11.4 to
75% [11]. Although hormone level changes were not
reported in the second study, Korkusuz et al. stated the
in 8 of the 9 subjects, euthyrosis was achieved or pre-
served, with the remaining one presented with a hidden
hyperthyroidism post treatment. Regarding to complica-
tions, no major complications were observed. The pain
experienced during and after HIFU treatment was also
recorded. On a VAS of 0 to 10, the median pain score
during treatment was 5.5, whilst it was 2 at the comple-
tion of the treatment. Interestingly, instead of pain from
actual treatment site, most patients reported pain
spreading to surrounding areas of the throat: neck,
scapula, arm, trapezius muscle [19].
Korkusuz et al. also looked at volume reduction, ef-
fects on thyroid function and immune response after
HIFU treatment in a different study [22]. Twelve pa-
tients with an average age of 56.7 years old were treated
with single-session HIFU. A volume reduction of more
than 30% was recorded in 9 of the 12 patients, whilst
the others did not achieve a 30% of reduction in nodule
volume [22]. Triiodothyronine, thyroxine, thyrotropin
and thyroglobulin were measured pre and post HIFU
ablation. No significant changes were recorded at all
follow-ups (24 h and 3 months) apart from thyroglobu-
lin, which could be used to monitor damages to thyroid
as well as thyroid mass [22]. Expectedly, a significant
surge in thyroglobulin level was recorded 24 h after
treatment but this was quickly normalized within the
following 3 months.
Kovatcheva et al. measured the effects of HIFU on
nodule volume at 1 week, 1 month, 3 months and
Fig. 1 A picture of the touch-screen interface of the HIFU device. The central panel represents the birdview reconstruction of the nodule made out of
multiple white cycles. The empty circles represent the unablated subunits while the filled circles represent the ablated subunits. The hyperechoic marks,
on the right, are a sign of tissue necrosis from the ablation
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6 months on 20 patients [23]. The mean amount of
depth-independent pulse acoustic energy received by
each nodule was 16.4 ± 7.7 kilojoules. There was no
significant difference in mean nodule volume 1 week
after HIFU treatment, although it was noted that the
nodule volume in 8 patients had increased by 4.7–35.1%
whilst a decrease of 2.3–28.6% in 12 patients. All 20
patients recorded a decrease in mean nodular volume
reduction at 1 month and 3 months, 26.3% ± 16.9 and
38.5% ± 21.6 respectively. 3 patients required a second
HIFU treatment due to insufficient reduction of nodule
volume (<30%) whilst another patient failed to follow-
up. Volume reduction of 48.7% ± 24.3 was noted in the
remaining 16 patients [23].
Recently, Lang et al. assessed the 6-month and 12-
month efficacy of single-session of HIFU in 22 pa-
tients [24]. The mean amount of depth-independent
acoustic energy to each nodule was 15.17 ± 6.90 kilo-
joules and the treatment time was 75.71 ± 34.20 min.
Unlike previous studies, the US-guided HIFU device
was updated with a new ablation software (Beamo-
tion) which shortened ablation time while maintain-
ing similar efficacy. Each voxel received a continuous
8-s pulse of HIFU energy followed by 40 s of cooling
time before the beam moved to the adjacent voxel.
This was a prospective study and had a group of
patients without receiving HIFU treatment (i.e. con-
trol group). The study assessed of symptoms as a re-
sult of treatment. The authors showed that the
application of HIFU ablation not only induced signifi-
cant 12-month nodule shrinkage from baseline (me-
dian = 76.04%) but also improved pressure symptom
score (from median = 5.0 at baseline to median = 3.0
at 6-month (p < 0.001) and median = 1.0; at 12-month
(p < 0.001)) as well as improved physical composite
score of Short form-12 at 12-month (median = 0.89;
p = 0.006) [24].
In addition to size shrinkage, changes in US pattern
of the nodules before and after HIFU treatment has
also been reported [23, 24]. For echogenicity, treated
nodules tended to become more hypoechoic while for
vascularization, blood flow tended to decrease over
time (Fig. 2). However, these parameters are generally
difficult to measure objectively.
Discussion
HIFU ablation could be considered a truly minimally in-
vasive procedure because it is able to induce irreversible
tissue necrosis via thermal ablation beneath the skin
without skin puncture or incision [7]. It has been found
to be successful in the treatment of many benign and
malignant tumors [13]. However, few studies have for-
mally evaluated its use in benign thyroid nodules. In our
systematic search, only 5 studies fulfilled inclusion cri-
teria [15, 19, 21–24]. As expected, they all demonstrated
the safety and feasibility of using a US-guided HIFU
device to induce short-term nodule shrinkage with one
study [24] even showing an improvement in local symp-
toms following treatment.
In terms of safety, there were no major concerns,
However, it appeared pain and discomfort during
treatment occurred commonly. Nevertheless, it is
worth noting that the pain quickly subsided once the
treatment had been completed and so, there was very
little persistent pain afterwards. Skin redness and mild
subcutaneous swelling were also commonly observed
Fig. 2 A picture showing the difference in intra-lesional contrast enhancement between an ablated and an un-ablated nodule
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over the nodule area but they tended to resolve
within the first 1–2 weeks. No major complications
such as recurrent laryngeal nerve palsy, skin burn or
haematoma were observed in any of the studies. Thy-
roid function seemed to be unaffected by the HIFU
ablation [22].
In terms of efficacy, relative to baseline, the mean
or median volume reduction ranged between 45 and
50% in the first 3 to 6 months [15, 19, 21]. However,
it is worth noting that only two recent studies re-
ported outcomes for 6 months or longer [23, 24].
The rest reported up to 3 months [15, 19, 21–24].
Consistent with the experience from other types of
thermal ablation, the treated nodule tended to con-
tinually shrink over time and so, the extent of nodule
shrinkage might continue for one or two years after-
wards. The risk of nodule regrowth tended to be un-
common but studies with longer follow-up period are
required [25]. The reported efficacies from HIFU were
variable but appeared comparable to those for other
thermal ablation techniques like RFA and LAT [24].
However, one should be aware that baseline nodule
characteristics tended to vary between studies and so
a direct comparison between techniques is impossible.
Recent studies appeared to report higher rates of effi-
cacy and this might be due to improved technique
and ablation software. In terms of costs, the initial
starting cost seemed to be much greater than that of
other techniques, mostly due to the high start-up cost
of the device (Table 3).
In terms of factors affecting treatment efficacy (as
measured by extent of nodule shrinkage), although early
echogenicity change, pre-ablation nodule size and vascu-
lar flow by Doppler pattern have been implicated, to
date, only one study was able to find pre-ablation nodule
volume as an independent significant factor. In this
study, nodules ≤8.2 mL was almost two times more
likely to have >50% nodule shrinkage at 12-month than
nodules >8.2 mL [24].
From our systematic search, there are several short-
comings related to HIFU ablation worth highlighting.
First, most of the thyroid nodules treated by HIFU
had been small in size/volume when compared to
studies evaluating other thermal ablation techniques
[10, 11]. This is because it takes a relatively long
time for a small and tight focused region to cover
the entire nodule volume (Table 3). On average,
using the current US-guided device, a well-selected
3 cm thyroid nodule would take approximately 45–
60 min for complete ablation while for either RFA or
LAT, this would be 30–40% less. Although it is pos-
sible to either increase the power or shorten the
cooling period by changing the current software
setting, the limiting factor with HIFU is the fact that
energy still needs to propagate through the skin and
deeper layers into the targeted nodule. Second, given
the few number of studies, there are still many
unanswered questions. For example, the efficacy of
ablation remains highly unpredictable with some
nodules showing a good response while others having
less adequate response. Third, with the current de-
vice, treatment pulses could only apply to one single
layer with a maximum treatment depth of 2.8 cm
under the skin. Nodules located in deeper or more
posterior part of the thyroid gland are currently not
treatable with HIFU ablation.
Conclusion
Despite the few number of studies, our review appeared
to suggest that HIFU is a safe and efficacious method of
treating symptomatic benign thyroid nodules. However,
larger-scale, prospective trials with longer follow-up
period are indeed required to further confirm this. In
terms of the ablation itself, relative to other thermal
ablation techniques, there are still much room for
improvements in terms of treatment duration and range
of treatable nodules.
Table 3 A comparison between different thermal techniques for benign thyroid nodules
Thermal technique Cost Treatment duration Main Usage
PEIT USD 50 – USD 100 5 to 10 mins Predominantly cystic benign thyroid nodules
RFA Equipment: USD 25000
Consumables: USD400 per session
~15 to 30 mins Solid functioning benign thyroid nodules
LAT Equipment with built in laser source: ~ USD12000
Nd:YAG laser source: ~USD15,000 to USD 20,000
Consumables: ~USD400 per session
~30 mins Cold nodules, autonomously functioning thyroid
nodules and cysts
Microwave ablation Equipment: USD 35000
Consumables: USD400 per session
~25 to 30 mins Predominantly solid or solid benign nodules
HIFU Equipment cost: ~USD 400,000
Annual maintenance: 10% of the base price
Consumables: ~USD 350 per treatment
~60–80 min Predominantly solid or solid benign nodules
Abbreviations: PEIT percutaneous ethanol injection therapy, RFA radiofrequency ablation, LAT laser ablation therapy, HIFU high intensity focused ultrasound
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